Entera Bio
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Entera Bio
Entera Bio Ltd. 是一家臨床階段的生物製藥公司，專注於口服大分子療法的開發和商業化，以滿足未滿足的醫療需求。公司的主要候選產品包括 EB612，該藥物正處於治療甲狀旁腺功能減退症的 II 期臨床試驗階段； EB613已完成治療骨質疏鬆症的II期臨床試驗，以及治療骨不連骨折的I期臨床試驗。該公司與安進公司就炎症性疾病和其他嚴重疾病領域的臨床候選藥物的開發和發現簽訂了研究合作和許可協議。 Entera Bio Ltd.成立於2009年，總部位於以色列耶路撒冷。
如何購買 Entera Bio (ENTX)
登入
1分鐘開戶
僅需1分鐘即可完成帳戶申請和驗證。整個過程完全自助，支援 RockFlow App 和網頁端操作。
充值資金
帳戶驗證完成後，您可以使用首選的支付方式向帳戶充值。
購買 ENTX
透過 RockFlow App 或網頁端搜尋 ENTX，輸入您想要投資的金額，然後點擊確認即可完成交易。
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.